139 related articles for article (PubMed ID: 22209174)
1. The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy.
Audet-Walsh É; Bellemare J; Lacombe L; Fradet Y; Fradet V; Douville P; Guillemette C; Lévesque É
Eur Urol; 2012 Jul; 62(1):88-96. PubMed ID: 22209174
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
3. Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway.
Lévesque E; Laverdière I; Audet-Walsh E; Caron P; Rouleau M; Fradet Y; Lacombe L; Guillemette C
Clin Cancer Res; 2014 Jun; 20(11):2971-83. PubMed ID: 24682418
[TBL] [Abstract][Full Text] [Related]
4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
6. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy.
Huang SP; Ting WC; Chen LM; Huang LC; Liu CC; Chen CW; Hsieh CJ; Yang WH; Chang TY; Lee HZ; Bao BY
Ann Surg Oncol; 2010 Jan; 17(1):312-22. PubMed ID: 19777185
[TBL] [Abstract][Full Text] [Related]
7. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
Malik RD; Goldberg JD; Hochman T; Lepor H
Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.
Ploussard G; Masson-Lecomte A; Beauval JB; Ouzzane A; Bonniol R; Buge F; Fadli S; Rouprêt M; Rebillard X; Gaschignard N; Pfister C; Villers A; Soulié M; Salomon L;
Urology; 2011 Sep; 78(3):607-13. PubMed ID: 21783233
[TBL] [Abstract][Full Text] [Related]
10. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
Briganti A; Joniau S; Gontero P; Abdollah F; Passoni NM; Tombal B; Marchioro G; Kneitz B; Walz J; Frohneberg D; Bangma CH; Graefen M; Tizzani A; Frea B; Karnes RJ; Montorsi F; Van Poppel H; Spahn M
Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925
[TBL] [Abstract][Full Text] [Related]
11. The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy.
Laverdière I; Flageole C; Audet-Walsh É; Caron P; Fradet Y; Lacombe L; Lévesque É; Guillemette C
Endocr Relat Cancer; 2015 Feb; 22(1):77-85. PubMed ID: 25452636
[TBL] [Abstract][Full Text] [Related]
12. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
[TBL] [Abstract][Full Text] [Related]
13. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
14. Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years.
Suardi N; Ficarra V; Willemsen P; De Wil P; Gallina A; De Naeyer G; Schatteman P; Montorsi F; Carpentier P; Mottrie A
Urology; 2012 Jan; 79(1):133-8. PubMed ID: 22088567
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
[TBL] [Abstract][Full Text] [Related]
16. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression.
Lévesque É; Huang SP; Audet-Walsh É; Lacombe L; Bao BY; Fradet Y; Laverdière I; Rouleau M; Huang CY; Yu CC; Caron P; Guillemette C
Clin Cancer Res; 2013 Feb; 19(3):699-709. PubMed ID: 23186779
[TBL] [Abstract][Full Text] [Related]
18. SRD5A polymorphisms and biochemical failure after radical prostatectomy.
Audet-Walsh E; Bellemare J; Nadeau G; Lacombe L; Fradet Y; Fradet V; Huang SP; Bao BY; Douville P; Girard H; Guillemette C; Lévesque E
Eur Urol; 2011 Dec; 60(6):1226-34. PubMed ID: 21715084
[TBL] [Abstract][Full Text] [Related]
19. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI
Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
[TBL] [Abstract][Full Text] [Related]
20. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT
J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
